^
Association details:
Biomarker:No biomarker
Cancer:Burkitt Lymphoma
Drug:Rituxan (rituximab) (CD20 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Excerpt:
MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with...Burkitt lymphoma (BL)…
Secondary therapy:
Chemotherapy
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Burkitt Lymphoma: Induction therapy <60 y…cytarabine + rituximab (regimen includes intrathecal therapy)
Secondary therapy:
cytarabine